Quidel Corporation (QDEL): Price and Financial Metrics
Quidel Corporation (QDEL)
Today's Latest Price: $97.81 USD
Updated Apr 1 6:55pm
Add QDEL to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
QDEL Stock Summary
- With a one year PEG ratio of 1,003.35, Quidel Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.11% of US stocks.
- QDEL's current price/earnings ratio is 49.22, which is higher than 90.28% of US stocks with positive earnings.
- The price/operating cash flow metric for Quidel Corp is higher than 90.24% of stocks in our set with a positive cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to Quidel Corp are APPF, MJCO, DHX, VNDA, and SLP.
- Visit QDEL's SEC page to see the company's official filings. To visit the company's web site, go to www.quidel.com.
QDEL Stock Price Chart More Charts
QDEL Price/Volume Stats
| Current price | $97.81 | 52-week high | $106.56 |
| Prev. close | $97.81 | 52-week low | $52.49 |
| Day low | $92.76 | Volume | 596,900 |
| Day high | $103.00 | Avg. volume | 432,144 |
| 50-day MA | $82.42 | Dividend yield | N/A |
| 200-day MA | $68.13 | Market Cap | 4.10B |
Quidel Corporation (QDEL) Company Bio
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
QDEL Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $97.81 | $327.97 | 235% |
We started the process of determining a valid price forecast for Quidel Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Quidel Corp ranked in the 68th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for QDEL, they are:
- In the past 5.31 years, Quidel Corp has a compound free cash flow growth rate of 0.71%; that's higher than 86.21% of free cash flow generating stocks in the Healthcare sector.
- 97% of the company's capital comes from equity, which is greater than 91.49% of stocks in our cash flow based forecasting set.
- The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 8.47% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 229% |
| 1% | 232% |
| 2% | 235% |
| 3% | 239% |
| 4% | 242% |
| 5% | 245% |
Want more companies with a valuation profile/forecast similar to that of Quidel Corp? See ABBV, FMS, RSCF, SEM, and AMN.
Loading social stream, please wait...